|
1
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hofmann HS, Neef H, Krohe K, Andreev P and
Silber RE: Prognostic factors and survival after pulmonary
resection of metastatic renal cell carcinoma. Eur Urol. 48:77–81.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arsanious A, Bjarnason GA and Yousef GM:
From bench to bedside: current and future applications of molecular
profiling in renal cell carcinoma. Mol Cancer. 8:202009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wood CG: Molecular markers of prognosis in
renal cell carcinoma: Insight into tumor biology helps define risk
and provides targets for therapy. J Surg Oncol. 94:264–265. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel C, Ahmed A and Ellsworth P: Renal
cell carcinoma: a reappraisal. Urol Nurs. 32:182–190.
2012.PubMed/NCBI
|
|
7
|
Maroto P and Rini B: Molecular biomarkers
in advanced renal cell carcinoma. Clin Cancer Res. 20:2060–2071.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aqeilan RI, Calin GA and Croce CM: miR-15a
and miR-16–1 in cancer: discovery, function and future
perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar
|
|
9
|
White NM, Khella HW, Grigull J, et al:
miRNA profiling in metastatic renal cell carcinoma reveals a
tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho WC: OncomiRs: the discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tiwari M: Microarrays and cancer
diagnosis. J Cancer Res Ther. 8:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perez-Diez A, Morgun A and Shulzhenko N:
Microarrays for cancer diagnosis and classification. Adv Exp Med
Biol. 593:74–85. 2007.PubMed/NCBI
|
|
13
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koberle V, Kronenberger B, Pleli T, et al:
Serum microRNA-1 and microRNA-122 are prognostic markers in
patients with hepatocellular carcinoma. Eur J Cancer. 49:3442–3449.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao A, Li G, Péoc’h M, Genin C and
Gigante M: Serum miR-210 as a novel biomarker for molecular
diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol.
94:115–120. 2013. View Article : Google Scholar
|
|
16
|
Patnaik SK, Kannisto E, Knudsen S and
Yendamuri S: Evaluation of microRNA expression profiles that may
predict recurrence of localized stage I non-small cell lung cancer
after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar
|
|
17
|
Guo QJ, Mills JN, Bandurraga SG, et al:
MicroRNA-510 promotes cell and tumor growth by targeting
peroxiredoxin1 in breast cancer. Breast Cancer Res. 15:R702013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu X, Zhang X, Bi T, et al: MiRNA
expression signature for potentially predicting the prognosis of
ovarian serous carcinoma. Tumour Biol. 34:3501–3508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen W, Tang Z, Sun Y, et al: miRNA
expression profile in primary gastric cancers and paired lymph node
metastases indicates that miR-10a plays a role in metastasis from
primary gastric cancer to lymph nodes. Exp Ther Med. 3:351–356.
2012.PubMed/NCBI
|
|
20
|
Guinan P, Sobin LH, Algaba F, et al: TNM
staging of renal cell carcinoma: Workgroup No. 3 Union
International Contre le Cancer (UICC) and the American Joint
Committee on Cancer (AJCC). Cancer. 80:992–993. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
White NM, Bao TT, Grigull J, et al: miRNA
profiling for clear cell renal cell carcinoma: biomarker discovery
and identification of potential controls and consequences of miRNA
dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu H, Brannon AR, Reddy AR, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: with
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sana J, Faltejskova P, Svoboda M and Slaby
O: Novel classes of non-coding RNAs and cancer. J Transl Med.
10:1032012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koscianska E, Baev V, Skreka K, et al:
Prediction and preliminary validation of oncogene regulation by
miRNAs. BMC Mol Biol. 8:792007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Volinia S, Galasso M, Costinean S, et al:
Reprogramming of miRNA networks in cancer and leukemia. Genome Res.
20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mikhaylova O, Stratton Y, Hall D, et al:
VHL-regulated MiR-204 suppresses tumor growth through inhibition of
LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell.
21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dey N, Das F, Ghosh-Choudhury N, et al:
microRNA-21 governs TORC1 activation in renal cancer cell
proliferation and invasion. PLoS One. 7:e373662012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White NM, Bao TT, Grigull J, et al: miRNA
profiling for clear cell renal cell carcinoma: Biomarker discovery
and identification of potential controls and consequences of miRNA
dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Brannon AR, Reddy AR, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krzeslak A: Akt kinase: a key regulator of
metabolism and progression of tumors. Postepy Hig Med Dosw
(Online). 64:490–503. 2010.In Polish.
|
|
33
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Macher-Goeppinger S, Bermejo JL, Wagener
N, et al: Expression and prognostic relevance of the death receptor
CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 301:203–211.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sejima T, Morizane S, Hinata N, et al: Fas
expression in renal cell carcinoma accurately predicts patient
survival after radical nephrectomy. Urol Int. 88:263–270. 2012.
View Article : Google Scholar : PubMed/NCBI
|
